ROCKVILLE, MD, UNITED STATES, January 7, 2019 /EINPresswire.com/ -- American Gene Technologies announced today that its Chief Executive Officer, Jeff Galvin, will attend the annual J.P. Morgan Healthcare Conference, held at the Westin St. Francis between January 7-10 in San Francisco, California. American Gene Technologies invitation to attend the conference follows recent discussions with J.P. Morgan and other biotechnology investment firms about AGT’s significant innovations in the industry.
Organized by J.P. Morgan, the J.P. Morgan Healthcare Conference is a four-day conference bringing together emerging fast-growth companies, members of the investment community, industry leaders, and innovative technology creators in healthcare. It is the industry’s largest healthcare investment conference.
Between January 7-10, American Gene Technologies’s CEO Jeff Galvin, CFO Neil Lyons, Norman Rogers, Drew Palin, and Morgan Stevens will also attend the following events in San Francisco: Redefining Early Stage Investments (RESI) Conference, Biotech Showcase, and BIO One-on-One Partnering. In all, they will participate in over 100 meetings.
About American Gene Technologies (AGT):
AGT is an emerging gene and cell therapeutics company with a proprietary lentiviral platform capable of broad applications including: large and orphan indications, infectious disease, immuno-oncology, and monogenic disorders. AGT expects to take its patented, lead candidate for an HIV Cure into the clinic in 2019. It has pioneered a novel immuno-oncology approach of stimulating gamma-delta (γδ) T cells to attack a variety of cancers. Four key patents in AGT’s novel immuno-oncology approach have been granted. AGT has a diverse portfolio of patent filings surrounding key tools and components in viral vectors, gene therapy, and regenerative medicine.